PHARMASGP HOLDING SE O.N. news, videos and press releases
For more news please use our advanced search feature.
PHARMASGP HOLDING SE O.N. - More news...
PHARMASGP HOLDING SE O.N. - More news...
- EQS-Adhoc: PharmaSGP Holding SE proposes an increased dividend of EUR 1.36 per share for 2023
- EQS-News: PharmaSGP exceeds the € 100 million revenues mark in 2023 and plans further profitable growth in 2024
- EQS-News: PharmaSGP continues the profitable growth course of the previous quarters in the third quarter of 2023
- EQS-News: PharmaSGP achieves top performance in the first half of 2023
- EQS-News: PharmaSGP Holding SE: Strong support at 2023 AGM for very successful business development
- EQS-News: PharmaSGP with a significant leap in revenue in Q1 2023 – EBITDA grows by more than 40%
- EQS-News: PharmaSGP plans dividend distribution of 49.2% after record year in 2022
- EQS-News: PharmaSGP confirms record revenue and record profitability for 2022 and publishes forecast for 2023
- EQS-Adhoc: PharmaSGP Holding SE releases forecast for full year 2023
- EQS-News: PharmaSGP achieves new record revenue of more than € 85.5 million for 2022 exceeding analysts’ expectations
- EQS-Adhoc: PharmaSGP Holding SE resolves on buyback program for own shares of up to 1.5 million Euro
- EQS-News: PharmaSGP posts record revenues (+39%) and record earnings (+54%) in 9M 2022 – raises full-year forecast
- EQS-Adhoc: PharmaSGP Holding SE raises forecast for FY 2022
- DGAP-News: PharmaSGP reports record revenues (+59%) and record earnings (+86%) in the first half of 2022
- DGAP-News: PharmaSGP successfully secures financing of up to € 160 million
- DGAP-News: PharmaSGP Holding SE successfully holds 2022 AGM
- DGAP-News: PharmaSGP: Another revenue record – Q1 2022 revenues up 67% year-on-year
- DGAP-News: PharmaSGP expects to see clear double-digit revenue and profit growth in 2022
- DGAP-News: PharmaSGP - Dividend at the upper end of the announced bandwidth after a record year in 2021
- DGAP-News: PharmaSGP achieves record results in 2021 - Adjusted EBITDA in Q4 up fivefold year-on-year
- DGAP-News: PharmaSGP achieves record revenues in 2021 and exceeds analysts' expectations
- DGAP-News: PharmaSGP reporting 34% revenue growth and increased profitability in Q3 2021
- DGAP-News: PharmaSGP: Product portfolio further expanded and internationalisation driven forward in H1 2021
- DGAP-Adhoc: PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio
- DGAP-News: PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK
- DGAP-News: PharmaSGP successfully holds first AGM after IPO
- DGAP-Adhoc: PharmaSGP Group acquires OTC brand portfolio (Baldriparan, Formigran, Spalt and Kamol) from GSK
- DGAP-News: PharmaSGP: Expected business development in Q1 2021
- DGAP-News: PharmaSGP: Revenue growth in 2020 despite declining markets
- DGAP-Adhoc: PharmaSGP Holding SE announces preliminary FY 2020 revenue and earnings trends after suspension of forecast